Ogeda is developing a drug called fezolinetant to treat hot flashes and night sweats caused by menopause, according to the report.
Astellas will pay $533 million upfront, along with $320 in milestone payments for the development of fezolinetant.
“The transaction fits with our strategy to deliver innovative drugs in therapeutic areas with high unmet medical needs,” Astellas President and CEO Yoshihiko Hatanaka said in a news release.
More articles on supply chain:
Viewpoint: US should strengthen existing laws to lower drug prices — not make new ones
Mexico border tax could lead to medical device shortages: 4 things to know
How SSM Health’s pharmacy concierge program helps patients manage high drug costs
